EverSource Wealth Advisors’s Matinas BioPharma MTNB Stock Holding History

EverSource Wealth Advisors’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37	Hold	60	–	–	﹤0.01%	4358
2026 Q1	$30	Hold	60	–	–	﹤0.01%	4342
2025 Q4	$35	Hold	60	–	–	﹤0.01%	4202
2025 Q3	$113	Hold	60	–	–	﹤0.01%	4182
2025 Q2	$53	Hold	60	–	–	﹤0.01%	4189
2025 Q1	$31	Hold	60	–	–	﹤0.01%	3944
2024 Q4	$31	Hold	60	–	–	﹤0.01%	3681
2024 Q3	$212	Hold	60	–	–	﹤0.01%	2956
2024 Q2	$484	Hold	60	–	–	﹤0.01%	2899
2024 Q1	$557	Hold	60	–	–	﹤0.01%	2691
2023 Q4	$649	Hold	60	–	–	﹤0.01%	2475
2023 Q3	$390	Hold	60	–	–	﹤0.01%	2420
2023 Q2	$1.08K	Hold	60	–	–	﹤0.01%	2197
2023 Q1	$1.41K	Hold	60	–	–	﹤0.01%	2033
2022 Q4	$1.5K	Buy	+60	New	+$2K	﹤0.01%	1989

Other funds holding MTNB

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HIW

Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

EverSource Wealth Advisors's MTNB Position: Q2 2026 in Review

EverSource Wealth Advisors held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 60 shares worth $37. The position accounts for ﹤0.01% of the portfolio, ranked #4358.

EverSource Wealth Advisors first reported a position in MTNB in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.5K in Q4 2022. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

EverSource Wealth Advisors held 60 shares of Matinas BioPharma worth $37 as of Q2 2026.
EverSource Wealth Advisors left its Matinas BioPharma share count unchanged in Q2 2026.
Matinas BioPharma made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4358 holding.
EverSource Wealth Advisors first reported a position in Matinas BioPharma in Q4 2022 and has held it in 15 quarters since.
EverSource Wealth Advisors's Matinas BioPharma position peaked at $1.5K in Q4 2022.
25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.